SAN DIEGO, California, April 29, 2026
Neurocrine Biosciences announced the publication of new peer-reviewed research in The Journal of Clinical Psychiatry establishing a clinically meaningful improvement threshold for the Tardive Dyskinesia Impact Scale (TDIS™). The findings provide critical validation for patient-reported outcome measures in assessing treatment benefits with INGREZZA® (valbenazine), a leading therapy for tardive dyskinesia (TD). This milestone strengthens the role of patient-centric clinical endpoints in neurology and psychiatry, addressing a long-standing gap where clinical observations alone fail to capture the full burden of disease.
TDIS Establishes Clear Benchmark for Clinical Improvement
The study defines a minimal clinically important difference (MCID) of four points in TDIS total score, offering a standardized benchmark to interpret meaningful patient improvement in clinical trials. TDIS is the first and only psychometrically validated patient-reported scale specifically designed for tardive dyskinesia, evaluating physical impairment, functional limitations, and socio-emotional distress caused by involuntary movements.
This advancement enables clinicians and researchers to quantify treatment impact more accurately, bridging the gap between objective clinical assessments and real-world patient experience. The research reinforces that movement severity does not fully reflect patient suffering, highlighting the importance of incorporating subjective patient feedback into therapeutic evaluation.
Clinical Data Reinforces INGREZZA’s Patient-Centered Benefits
Advertisement
The publication builds on data from the KINECT® clinical program, including KINECT-3, KINECT-4, and KINECT-PRO™ studies, demonstrating that patients treated with INGREZZA® achieved clinically meaningful improvements across physical, social, and emotional domains. These improvements aligned with clinician-rated movement severity reductions and global assessments, confirming the reliability of TDIS as a robust clinical endpoint.
Notably, KINECT-PRO™, the first study focused on patient-reported outcomes in TD, further validated that VMAT2 inhibition therapy can significantly improve quality of life beyond symptom control. The results highlight INGREZZA’s ability to deliver consistent therapeutic benefits across diverse patient populations and real-world clinical settings.
Advancing Patient-Centered Drug Development in Neurology
This development marks a broader shift toward patient-focused drug evaluation frameworks, where quality of life metrics and real-world impact are becoming central to regulatory and clinical decision-making. By establishing a clear and validated threshold for meaningful improvement, Neurocrine Biosciences enhances the interpretability of clinical trial data, supporting more informed treatment decisions and regulatory evaluations. Tardive dyskinesia, a condition affecting an estimated 800,000 adults in the U.S., remains a significant unmet medical need, often associated with long-term use of antipsychotic medications.
The integration of validated patient-reported outcome tools like TDIS™ into clinical research represents a critical advancement in precision medicine and neuroscience, ensuring therapies are evaluated based on real patient benefit rather than solely clinical metrics. With strong clinical evidence and validated outcome measures, Neurocrine Biosciences continues to strengthen its leadership in neurological drug development, improving both treatment assessment standards and patient outcomes in movement disorders.
Source: Neurocrine Biosciences press release
